The Clinical Trials Research Office (CTRO) provides the infrastructure and facilitates the coordination necessary to support high quality clinical research in a matrix style cancer center. The science supported by the CTRO encompasses all levels and types of clinical trials, from pilot studies and phase I protocols through phase II and III protocols. These protocols may be UWCCC investigator-initiated institutional or industry sponsored clinical trials, or they may be NCI-sponsored clinical trials funded through the cooperative group, phase I, or research grant mechanisms. The CTRO infrastructure for clinical research supported by the CCSG grant is designed to facilitate and promote clinical research by providing effective mechanisms for quality control and efficiency. The UWCCC core component of the CTRO provides a basic level of protocol- specific support for all UWCCC clinical trials. This includes process coordination; protocol activation and closure; tracking by the UWCCC data base; regulatory review and compliance; patient registration and randomization; and quality assurance. The CTRO supports the Protocol Review and Monitoring System, providing checkpoints for quality control and for enforcement of the institutional authority to open and close protocols. It ensures complete reports on protocol activity and meaningful cancer center supervision of the cancer clinical research in the institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014520-27S2
Application #
6217223
Study Section
Project Start
1999-04-16
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
27
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Elsaid, Mohamed Y; Shahi, Ankita; Wang, Albert R et al. (2018) Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog. Mol Cancer Ther 17:2320-2328
Dennison, Kirsten L; Chack, Aaron C; Hickman, Maureen Peters et al. (2018) Ept7, a quantitative trait locus that controls estrogen-induced pituitary lactotroph hyperplasia in rat, is orthologous to a locus in humans that has been associated with numerous cancer types and common diseases. PLoS One 13:e0204727
Zaitoun, Ismail S; Cikla, Ulas; Zafer, Dila et al. (2018) Attenuation of Retinal Vascular Development in Neonatal Mice Subjected to Hypoxic-Ischemic Encephalopathy. Sci Rep 8:9166
Hart, Vicki; Trentham-Dietz, Amy; Berkman, Amy et al. (2018) The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. Qual Life Res 27:1237-1247
Lee, Hye Jin; Ehlerding, Emily B; Cai, Weibo (2018) Antibody-Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases. Chembiochem :
Albertini, Mark R; Yang, Richard K; Ranheim, Erik A et al. (2018) Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother 67:1647-1658
Saghiri, Mohammad Ali; Asatourian, Armen; Nguyen, Eric H et al. (2018) Hydrogel Arrays and Choroidal Neovascularization Models for Evaluation of Angiogenic Activity of Vital Pulp Therapy Biomaterials. J Endod 44:773-779
Jamali, Nasim; Sorenson, Christine M; Sheibani, Nader (2018) Vitamin D and regulation of vascular cell function. Am J Physiol Heart Circ Physiol 314:H753-H765
Liu, Zhen; Ehlerding, Emily B; Cai, Weibo et al. (2018) One-step synthesis of an 18F-labeled boron-derived methionine analog: a substitute for 11C-methionine? Eur J Nucl Med Mol Imaging 45:582-584
Chakravarty, Rubel; Siamof, Cerise M; Dash, Ashutosh et al. (2018) Targeted ?-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. Am J Nucl Med Mol Imaging 8:247-267

Showing the most recent 10 out of 1528 publications